1 / 1

Conclusion

RANDOMISED CLINICAL TRIAL OF PERIOPERATIVE OMEGA-3 FATTY ACID SUPPLEMENTS IN ELECTIVE COLORECTAL CANCER SURGERY. Lone Schmidt Sørensen¹ ; Ole Thorlacius-Ussing 1 ; Erik. B. Schmidt² ; Henrik H. Rasmussen³ ; S. Lundbye-Christensen²; P. C. Calder 4 ; K. Lindorff-Larsen⁵

ania
Télécharger la présentation

Conclusion

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. RANDOMISED CLINICAL TRIAL OF PERIOPERATIVE OMEGA-3 FATTY ACID SUPPLEMENTS IN ELECTIVE COLORECTAL CANCER SURGERY Lone Schmidt Sørensen¹; Ole Thorlacius-Ussing1; Erik. B. Schmidt²; Henrik H. Rasmussen³; S. Lundbye-Christensen²;P. C. Calder4; K. Lindorff-Larsen⁵ ¹Department of Gastrointestinal Surgery, Aalborg University Hospital; ²Department of Cardiology, Centre for Cardiovascular Research, Aalborg University Hospital;³Centre for Nutrition and Bowel Disease, Aalborg University Hospital; 4Human Development and Health Academic Unit, Faculty of Medicine, University of Southampton, Southampton, UK and National Institute for Health Research Southampton Biomedical Research Centre, University Hospital Southampton NHS Foundation Trust and University of Southampton, Southampton, UK; 5NordSim, Centre for Simulation, Skills Training, Science and Innovation, Aalborg University Hospital Results: In total 148 consecutive patients (68 females, 80 males; mean age 71 (range 41-89) years) were randomised. There was no significant difference between groups regarding infectious or non-infectious postoperative complications (P = 1.000). Granulocyte levels of EPA, DHA and docosapentaenoic acid (DPA) were significantly higher (P < 0.001) in the active compared with the control group. AA in granulocytes was significantly lower (P< 0.001) in the active group compared with the control group. Background: Omega-3 fatty acids (n-3 FA) may have beneficial clinical effects and n-3 FA supplements may improve outcome after surgery Methods: In a randomised, double-blind, prospective, placebo-controlled, single-centre trial, patients referred for elective colorectal cancer surgery, received either an n-3 FA-enriched oral nutritional supplement (ONS) (Supportan® Fresenius Kabi, Bad Homburg Germany; 200 ml twice daily) providing 2.0 g of eicosapentaenoic acid (EPA) and 1.0 g of docosahexaenoic acid (DHA) per day or a standard isocaloric and isonitrogenous ONS for 7 days before and 7 days after surgery. Primary endpoint was infectious and non-infectious complications within 30 postoperative days. Secondary endpoints were length of stay in hospital, intensive care unit stay, readmissions and concentrations of marine n-3 FA and arachidonic acid (AA) in granulocyte membranes. Table 7 Granulocyte FA on day of operation in the control and active groups Data are median (IQR) percentage of the total FA content (weight %) *** P < 0.001 vs. control group Conclusion EPA, DHA and DPA were incorporated into granulocytes in patients receiving n-3 FA, but this was not associated with improved postoperative outcomes Contact Lone Schmidt Sørensen lss@rn.dk Conflicts of interest: None to declare

More Related